• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于粪便免疫化学试验的结直肠癌筛查方案的长期效果。

Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.

机构信息

Registro Tumori del Veneto, Regione del Veneto, Padova, Italy.

Gastroenterology Unit, Nuovo Regina Margherita Hospital, Rome, Italy.

出版信息

Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3.

DOI:10.1136/gutjnl-2017-314753
PMID:29101260
Abstract

BACKGROUND

The long-term performance of colorectal cancer (CRC) screening programmes based on a 2-year faecal immunochemical test (FIT) is still unclear.

METHODS

In a sample of 50 to 69-year-olds repeatedly screened with the FIT (OC-Hemodia latex agglutination test; cut-off: 20 µg haemoglobin/g faeces), we examined: (1) the FIT positivity rate, the CRC and advanced adenoma detection rate and the FIT's positive predictive value (PPV) for advanced neoplasia, at each round of screening and (2) the cumulative CRC and advanced adenoma detection rate after five rounds of FIT.

RESULTS

Over 12 years (2002-2014), 123 347 individuals were administered the FIT up to six times, and 781 CRCs and 4713 advanced adenomas were diagnosed. The CRC and advanced adenoma detection rates declined substantially from the first to the third (rate ratio (RR) 0.25, 95% CI 0.20 to 0.32) and second (RR 0.51, 95% CI 0.47 to 0.56) rounds, respectively, and then remained stable. The PPV for advanced neoplasia dropped by 18% in the second round (RR 0.82, 95% CI 0.77 to 0.89), with no further reduction thereafter due to a concomitant decline in the FIT positivity rate (RR first to sixth rounds: 0.56, 95% CI 0.53 to 0.60).The cumulative CRC and advanced adenoma detection rates over five consecutive rounds were 8.5‰ (95% CI 7.8 to 9.2), and 58.9‰ (95% CI 56.9 to 61.0), respectively.

CONCLUSIONS

Repeated FIT significantly reduces the burden of colorectal disease while facilitating an efficient use of colonoscopy resources. The cumulative detection rate after five rounds of FIT is similar to primary screening with colonoscopy, supporting the need to account for the cumulative sensitivity of repeated FITs when evaluating the test's efficacy.

摘要

背景

基于每两年进行一次粪便免疫化学检测(FIT)的结直肠癌(CRC)筛查项目的长期效果仍不明确。

方法

在一个通过 FIT(OC-Hemodia 乳胶凝集试验;截断值:20μg 血红蛋白/g 粪便)反复筛查的 50 岁至 69 岁人群样本中,我们检测了:(1)在每轮筛查时的 FIT 阳性率、CRC 和高级腺瘤检出率以及 FIT 对高级肿瘤的阳性预测值(PPV),以及(2)在进行了五轮 FIT 后,CRC 和高级腺瘤的累积检出率。

结果

在 12 年(2002 年至 2014 年)期间,共有 123347 人接受了最多六次的 FIT 检测,并诊断出 781 例 CRC 和 4713 例高级腺瘤。CRC 和高级腺瘤的检出率从第一轮(率比(RR)0.25,95%CI 0.20 至 0.32)和第二轮(RR 0.51,95%CI 0.47 至 0.56)筛查开始显著下降,之后一直保持稳定。第二轮的高级肿瘤 PPV 下降了 18%(RR 0.82,95%CI 0.77 至 0.89),此后由于 FIT 阳性率的下降(RR 第一至第六轮:0.56,95%CI 0.53 至 0.60),PPV 没有进一步下降。连续五轮的 CRC 和高级腺瘤累积检出率分别为 8.5‰(95%CI 7.8 至 9.2)和 58.9‰(95%CI 56.9 至 61.0)。

结论

重复的 FIT 显著降低了结直肠疾病的负担,同时促进了结肠镜检查资源的有效利用。五轮 FIT 后的累积检出率与结肠镜初筛相似,这支持在评估该检测的效果时,需要考虑重复 FIT 的累积敏感性。

相似文献

1
Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.基于粪便免疫化学试验的结直肠癌筛查方案的长期效果。
Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3.
2
Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.粪便血红蛋白浓度在 FIT 结果阴性的人群中与后续轮次的肿瘤检出率相关:意大利基于人群筛查项目的前瞻性研究。
Gut. 2020 Mar;69(3):523-530. doi: 10.1136/gutjnl-2018-318198. Epub 2019 Aug 27.
3
Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.两种粪便免疫化学检测试验在不同阳性截断值下检测晚期肿瘤的性能:荷兰国家结直肠癌筛查计划的一项横断面研究。
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):111-118. doi: 10.1016/S2468-1253(18)30319-4. Epub 2018 Nov 27.
4
Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.单份样本与双份粪便免疫化学试验在基于人群的结直肠癌筛查中的多次检测:一项基于人群的研究。
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):622-631. doi: 10.1016/S2468-1253(19)30176-1. Epub 2019 Jun 10.
5
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
6
Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.粪便免疫化学试验与结肠镜检查用于息肉切除术后监测的比较:一项准确性、可接受性和经济学研究。
Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010.
7
Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.粪便免疫化学检测与结肠镜检查在家族性结直肠癌筛查中的等效性。
Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.
8
Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.粪便免疫化学检测筛查项目中近端和远端晚期腺瘤的长期检出率差异:一项回顾性队列研究。
Ann Intern Med. 2018 Nov 6;169(9):602-609. doi: 10.7326/M18-0855. Epub 2018 Oct 2.
9
Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.粪便血红蛋白可定义结直肠腺瘤性息肉患者在结直肠肿瘤筛查中风险。
United European Gastroenterol J. 2020 Jun;8(5):559-566. doi: 10.1177/2050640620913674. Epub 2020 Mar 16.
10
Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.粪便血红蛋白浓度与下一轮筛查中晚期结直肠肿瘤的检测有关。
J Med Screen. 2017 Jun;24(2):62-68. doi: 10.1177/0969141316653983. Epub 2016 Jul 1.

引用本文的文献

1
Prevalence of Hepatitis C in the Emilia-Romagna Region of Italy: Population-Wide Screening.意大利艾米利亚-罗马涅地区丙型肝炎的患病率:全人群筛查
Viruses. 2025 Jun 12;17(6):843. doi: 10.3390/v17060843.
2
The Impact of Age on Preferences for Colorectal Cancer Surveillance Strategies: Are Fecal Immunochemical Tests FIT for Surveillance?年龄对结直肠癌监测策略偏好的影响:粪便免疫化学检测是否适合用于监测?
Cancer Med. 2025 Mar;14(5):e70723. doi: 10.1002/cam4.70723.
3
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.
粪便和血液生物标志物在结直肠癌管理中的应用:筛查和疾病监测的最新进展。
Mol Cancer. 2024 Nov 19;23(1):259. doi: 10.1186/s12943-024-02174-w.
4
Cost-utility analysis of real-time artificial intelligence-assisted colonoscopy in Italy.意大利实时人工智能辅助结肠镜检查的成本效用分析
Endosc Int Open. 2023 Nov 10;11(11):E1046-E1055. doi: 10.1055/a-2136-3428. eCollection 2023 Nov.
5
Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.基于粪便免疫化学试验的筛查方案中,阴性结肠镜检查后的结肠镜检查间期结直肠癌。
Endoscopy. 2023 Dec;55(12):1061-1069. doi: 10.1055/a-2136-6564. Epub 2023 Oct 4.
6
Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.在瑞典基于人群的筛查项目中,采用粪便免疫化学检测的性别特异性临界值进行两轮筛查后出现的间隔期癌症。
J Med Screen. 2024 Mar;31(1):8-14. doi: 10.1177/09691413231185722. Epub 2023 Jul 16.
7
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds.筛查可及的 76-85 岁人群粪便潜血阴性 1 年后结直肠癌发病及死亡风险
Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1382-1390. doi: 10.1158/1055-9965.EPI-23-0265.
8
Cost-effectiveness of Artificial Intelligence-Aided Colonoscopy for Adenoma Detection in Colon Cancer Screening.人工智能辅助结肠镜检查在结肠癌筛查中检测腺瘤的成本效益
J Can Assoc Gastroenterol. 2023 Apr 7;6(3):97-105. doi: 10.1093/jcag/gwad014. eCollection 2023 Jun.
9
Age at cancer diagnosis by breed, weight, sex, and cancer type in a cohort of more than 3,000 dogs: Determining the optimal age to initiate cancer screening in canine patients.在一个超过 3000 只犬的队列中,按品种、体重、性别和癌症类型划分的癌症诊断年龄:确定犬患者开始癌症筛查的最佳年龄。
PLoS One. 2023 Feb 1;18(2):e0280795. doi: 10.1371/journal.pone.0280795. eCollection 2023.
10
Cancer detection in clinical practice and using blood-based liquid biopsy: A retrospective audit of over 350 dogs.临床实践中的癌症检测和基于血液的液体活检:超过 350 只狗的回顾性审计。
J Vet Intern Med. 2023 Jan;37(1):258-267. doi: 10.1111/jvim.16616. Epub 2023 Jan 20.